

Company Number: 766272

**Rainbow Medical Ventures Limited**

**Abridged Unaudited Financial Statements**

**for the financial period from 20 June 2024 (date of incorporation) to 31 August  
2025**

# Rainbow Medical Ventures Limited

## CONTENTS

	<b>Page</b>
Director's Responsibilities Statement	3
Balance Sheet	4
Notes to the Financial Statements	5 - 6

# Rainbow Medical Ventures Limited

## DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial period from 20 June 2024 (date of incorporation) to 31 August 2025

The director made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial period. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The director approves these financial statements and confirms that they is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they has made available to Edward Daly & Co., (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial period from 20 June 2024 (date of incorporation) to 31 August 2025."

### Signed on behalf of the board

**Michael Buckley**  
Director

28 January 2026

# Rainbow Medical Ventures Limited

## BALANCE SHEET

as at 31 August 2025

	Notes	Aug 25 €
<b>Current Assets</b>		
Cash at bank and in hand		79,956
<b>Creditors: amounts falling due within one year</b>	5	(17,718)
<b>Net Current Assets</b>		<u>62,238</u>
<b>Total Assets less Current Liabilities</b>		<u><u>62,238</u></u>
<b>Capital and Reserves</b>		
Called up share capital presented as equity		100
Retained earnings	6	62,138
<b>Shareholders' Funds</b>		<u><u>62,238</u></u>

I as Director of Rainbow Medical Ventures Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

**Approved by the board on 28 January 2026 and signed on its behalf by:**

**Michael Buckley**  
Director

# Rainbow Medical Ventures Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period from 20 June 2024 (date of incorporation) to 31 August 2025

### 1. General Information

Rainbow Medical Ventures Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 766272. The registered office of the company is Unit 6A, Cobh Retail Park, Ticknock, Cobh, Co. Cork. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

#### Statement of compliance

The financial statements of the company for the financial period ended 31 August 2025 have been prepared on the going concern basis and in accordance with FRS 105 "The Financial Reporting Standard for Micro-Entities applicable in the UK and Republic of Ireland" (FRS 105).

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial period, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

#### Accounting Convention

The financial statements are prepared under the historical cost convention.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

#### Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

#### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Transactions, during the financial period, which are denominated in foreign currencies are translated at the rates of exchange ruling at the date of the transaction. The resulting exchange differences are dealt with in the Profit and Loss Account.

#### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Period of financial statements

The financial statements are for the 14 month 12 days period from 20 June 2024 (date of incorporation) to 31 August 2025.

## Rainbow Medical Ventures Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period from 20 June 2024 (date of incorporation) to 31 August 2025

#### 4. Employees

The average monthly number of employees, including director, during the financial period was 3, (Jun 24 - 0).

	<b>Aug 25 Number</b>
Administration	2
Sales	1
	<u>3</u>

#### 5. Creditors Amounts falling due within one year

	<b>Aug 25 €</b>
Taxation	10,501
Other creditors	399
Accruals	6,818
	<u>17,718</u>

#### 6. Profit and loss account

	<b>Aug 25 €</b>
At 20 June 2024	-
Profit for the financial period	<u>62,138</u>
At 31 August 2025	<u>62,138</u>

#### 7. Capital commitments

The company had no material capital commitments at the financial period-ended 31 August 2025.

#### 8. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial period-end.

#### 9. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 28 January 2026.